The combination of chemotherapy and intraperitoneal MegaFas Ligand improves treatment of ovarian carcinoma

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

Deborah K. Armstrong, Brian N. Bundy, Lari Wenzel et al. · New England Journal of Medicine · 2006 · 2.6K citations · Full text

Medicine, Gynecology, Oncology +14

Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study

Robert F. Ozols, Brian N. Bundy, Benjamin E. Greer et al. · Journal of Clinical Oncology · 2003 · 2.1K citations

Medicine, Gynecology, Oncology +17

Lethal effect of the anti-Fas antibody in mice

Jun Ogasawara, Rie Watanabe‐Fukunaga, Masashi Adachi et al. · Nature · 1993 · 1.9K citations

Life Sciences, Immunology, Pathology +14

Monoclonal Antibody-Mediated Tumor Regression by Induction of Apoptosis

B. C. Trauth, C Klas, Anke Peters et al. · Science · 1989 · 1.7K citations · Full text

Life Sciences, Cell Biology, Oncology +17

Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer

David S. Alberts, P. Y. Liu, Edward V. Hannigan et al. · New England Journal of Medicine · 1996 · 1.2K citations · Full text

Medicine, Oncology, Surgery +5